Loading...
Aspirin is effective for secondary prevention of adverse cardiovascular events, but its specific value for primary prevention in patients with type 2 diabetes is less clear. In this Japanese study, 2539 adults (mean age, 65) with type 2 diabetes but no evidence of cardiovascular disease (CVD) were randomized to daily low-dose aspirin (81–100 mg) or no aspirin. Roughly 50% to 60% of patients were current or former smokers, had hypertension, or had dyslipidemia.
During a median follow-up of 4.4 years, the incidence of cardiovascular events (death, myocardial infarction, angina, and stroke) was similar in the aspirin and nonaspirin groups (roughly 6%). In subgroup analyses, a barely significant 32% relative reduction in overall risk was observe…